vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与合众银行（OSBC）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是合众银行的1.6倍（$152.6M vs $93.8M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 27.3%，领先7.2%），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 15.1%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
合众银行是一家总部位于美国明尼阿波利斯、在特拉华州注册的美国跨国银行机构。截至2025年，它是美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构，主营银行、投资、抵押等金融服务。
CPRX vs OSBC — 直观对比
营收规模更大
CPRX
是对方的1.6倍
$93.8M
净利率更高
CPRX
高出7.2%
27.3%
两年增速更快
CPRX
近两年复合增速
15.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $93.8M |
| 净利润 | $52.7M | $25.6M |
| 毛利率 | 82.9% | — |
| 营业利润率 | 40.5% | — |
| 净利率 | 34.5% | 27.3% |
| 营收同比 | 7.6% | — |
| 净利润同比 | -5.8% | 159.2% |
| 每股收益（稀释后） | $0.40 | $0.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRXOSBC
| Q1 26 | — | $93.8M | ||
| Q4 25 | $152.6M | $95.2M | ||
| Q3 25 | $148.4M | $95.9M | ||
| Q2 25 | $146.6M | $75.1M | ||
| Q1 25 | $141.4M | $73.1M | ||
| Q4 24 | $141.8M | $73.2M | ||
| Q3 24 | $128.7M | $71.2M | ||
| Q2 24 | $122.7M | $70.8M |
净利润CPRXOSBC
| Q1 26 | — | $25.6M | ||
| Q4 25 | $52.7M | — | ||
| Q3 25 | $52.8M | $9.9M | ||
| Q2 25 | $52.1M | $21.8M | ||
| Q1 25 | $56.7M | $19.8M | ||
| Q4 24 | $55.9M | — | ||
| Q3 24 | $43.9M | $23.0M | ||
| Q2 24 | $40.8M | $21.9M |
毛利率CPRXOSBC
| Q1 26 | — | — | ||
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | — | ||
| Q2 25 | 85.9% | — | ||
| Q1 25 | 87.3% | — | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — |
营业利润率CPRXOSBC
| Q1 26 | — | — | ||
| Q4 25 | 40.5% | 41.2% | ||
| Q3 25 | 44.7% | 13.6% | ||
| Q2 25 | 45.2% | 38.9% | ||
| Q1 25 | 44.8% | 35.8% | ||
| Q4 24 | 44.3% | 34.7% | ||
| Q3 24 | 39.6% | 41.9% | ||
| Q2 24 | 44.2% | 41.2% |
净利率CPRXOSBC
| Q1 26 | — | 27.3% | ||
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.6% | 10.3% | ||
| Q2 25 | 35.6% | 29.0% | ||
| Q1 25 | 40.1% | 27.1% | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 34.1% | 32.3% | ||
| Q2 24 | 33.2% | 30.9% |
每股收益（稀释后）CPRXOSBC
| Q1 26 | — | $0.48 | ||
| Q4 25 | $0.40 | $0.53 | ||
| Q3 25 | $0.42 | $0.18 | ||
| Q2 25 | $0.41 | $0.48 | ||
| Q1 25 | $0.45 | $0.43 | ||
| Q4 24 | $0.44 | $0.42 | ||
| Q3 24 | $0.35 | $0.50 | ||
| Q2 24 | $0.33 | $0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $115.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $893.3M |
| 总资产 | $1.1B | $6.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CPRXOSBC
| Q1 26 | — | $115.7M | ||
| Q4 25 | $709.2M | $124.0M | ||
| Q3 25 | $689.9M | $116.5M | ||
| Q2 25 | $652.8M | $141.8M | ||
| Q1 25 | $580.7M | $256.1M | ||
| Q4 24 | $517.6M | $99.3M | ||
| Q3 24 | $442.3M | $115.8M | ||
| Q2 24 | $375.7M | $120.9M |
股东权益CPRXOSBC
| Q1 26 | — | $893.3M | ||
| Q4 25 | $954.3M | $896.8M | ||
| Q3 25 | $920.2M | $866.7M | ||
| Q2 25 | $856.0M | $718.6M | ||
| Q1 25 | $794.3M | $694.5M | ||
| Q4 24 | $727.6M | $671.0M | ||
| Q3 24 | $660.9M | $661.4M | ||
| Q2 24 | $608.7M | $619.3M |
总资产CPRXOSBC
| Q1 26 | — | $6.8B | ||
| Q4 25 | $1.1B | $6.9B | ||
| Q3 25 | $1.1B | $7.0B | ||
| Q2 25 | $971.9M | $5.7B | ||
| Q1 25 | $908.9M | $5.7B | ||
| Q4 24 | $851.4M | $5.6B | ||
| Q3 24 | $772.0M | $5.7B | ||
| Q2 24 | $706.4M | $5.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | — |
| 自由现金流经营现金流 - 资本支出 | $44.9M | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CPRXOSBC
| Q1 26 | — | — | ||
| Q4 25 | $44.9M | $122.3M | ||
| Q3 25 | $32.4M | $35.9M | ||
| Q2 25 | $71.3M | $24.2M | ||
| Q1 25 | $60.0M | $17.8M | ||
| Q4 24 | $70.9M | $131.5M | ||
| Q3 24 | $72.9M | $48.5M | ||
| Q2 24 | $64.1M | $11.6M |
自由现金流CPRXOSBC
| Q1 26 | — | — | ||
| Q4 25 | $44.9M | $117.8M | ||
| Q3 25 | — | $34.7M | ||
| Q2 25 | $71.3M | $23.5M | ||
| Q1 25 | — | $16.2M | ||
| Q4 24 | $70.8M | $120.7M | ||
| Q3 24 | $72.6M | $46.2M | ||
| Q2 24 | $64.1M | $8.7M |
自由现金流率CPRXOSBC
| Q1 26 | — | — | ||
| Q4 25 | 29.4% | 123.7% | ||
| Q3 25 | — | 36.2% | ||
| Q2 25 | 48.6% | 31.2% | ||
| Q1 25 | — | 22.2% | ||
| Q4 24 | 49.9% | 165.0% | ||
| Q3 24 | 56.4% | 64.9% | ||
| Q2 24 | 52.3% | 12.3% |
资本支出强度CPRXOSBC
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 4.7% | ||
| Q3 25 | 0.0% | 1.3% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.1% | 14.7% | ||
| Q3 24 | 0.2% | 3.3% | ||
| Q2 24 | 0.0% | 4.2% |
现金转化率CPRXOSBC
| Q1 26 | — | — | ||
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | 3.64× | ||
| Q2 25 | 1.37× | 1.11× | ||
| Q1 25 | 1.06× | 0.90× | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | 2.11× | ||
| Q2 24 | 1.57× | 0.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
OSBC
| Net Interest Income | $81.1M | 87% |
| Noninterest Income | $12.6M | 13% |
